BT-11 - CAS 1912399-75-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
BT-11, the extract of dried root of Polygala tenuifolia Willdenow, is an orally available LANCL2 binding compound for treating inflammatory bowel disease. In addition, BT-11 inhibited acetylcholinesterase (AChE) activity in a dose-dependent and non-competitive manner (IC50= 263.7 μg/ml).
DMSO: ≥30 mg/mL
Store in a cool and dry place (or refer to the Certificate of Analysis).
Boiling Point:
923.4±75.0 ℃ at 760 Torr
1.424±0.06 g/cm3
Canonical SMILES:
1.Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.
Leber A;Hontecillas R;Zoccoli-Rodriguez V;Bassaganya-Riera J Inflamm Bowel Dis. 2018 Apr 28. doi: 10.1093/ibd/izy167. [Epub ahead of print]
Background: ;Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine synthetase C-like 2 (LANCL2) and has a benign safety profile in rats.;Methods: ;Mdr1a-/-, dextran sodium sulphate , and adoptive transfer mouse models of colitis were employed to validate therapeutic efficacy and characterize the mechanisms of therapeutic efficacy of BT-11. In vitro cultures of CD4+ T cell differentiation and human peripheral blood mononuclear cells from Crohn's disease patients were used to determine its potential for human translation.;Results: ;BT-11 reduces inflammation in multiple mouse models of IBD. Oral treatment with BT-11 increases the numbers of lamina propria regulatory T cells (Tregs) in a LANCL2-dependent manner. In vitro, BT-11 increases the differentiation in Treg phenotypes, the upregulation of genes implicated in Treg cell stability, and conditions Treg cells to elicit greater suppressive actions. These immunoregulatory effects are intertwined with the ability of BT-11 to regulate late stage glycolysis and tricarboxylic acid cycle.
2.Effects of BT-11 on memory in healthy humans.
Lee JY;Kim KY;Shin KY;Won BY;Jung HY;Suh YH Neurosci Lett. 2009 Apr 24;454(2):111-4. doi: 10.1016/j.neulet.2009.03.024. Epub 2009 Mar 11.
We previously reported that BT-11, the extract of dried roots of Polygala tenuifolia Willdenow, had neuroprotective effects and improved scopolamine- and stress-induced amnesia in rats. It also blocked the activity of acetylcholinesterase and enhanced glucose utilization in the rat brain. Therefore, we examined whether BT-11 could enhance memory in healthy humans. This study was a randomized, double-blind, placebo-controlled, parallel-group study of BT-11 in healthy adults. The participants were given capsules of BT-11 or placebo 3 times daily for 4 weeks. The Korean version of the California Verbal Learning Test (K-CVLT) and the Self-Ordered Pointing Test (SOPT) were used to assess verbal memory and working memory, respectively. The subjects in BT-11-treated group showed more significant increases in immediate recall on the K-CVLT than those in the placebo-treated group. In a comparison within each group, the subjects' scores on most subtests of the K-CVLT were significantly increased by both placebo and BT-11 treatment. Interestingly, the subjects' scores on the recognition subtest of the K-CVLT were significantly increased by BT-11 treatment but not by placebo treatment. Also, BT-11 treatment significantly reduced the number of errors on the SOPT, whereas placebo treatment did not.
3.An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease.
Carbo A;Gandour RD;Hontecillas R;Philipson N;Uren A;Bassaganya-Riera J J Med Chem. 2016 Nov 23;59(22):10113-10126. Epub 2016 Nov 15.
Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610) were screened by molecular docking, then synthesized and analyzed for binding to LANCL2 by surface plasmon resonance. Piperazine-1,4-diylbis(6-benzo[d]imidazole-2-yl)pyridine-2-yl)methanone, 7, was identified as the lead LANCL2-binding compound for treating IBD. The oral treatment with 7 (8 mg/kg/d) in a mouse model of IBD resulted in lowering the disease activity index, decreasing colonic inflammatory lesions by 4-fold, and suppressing inflammatory markers (e.g., TNF-α, and interferon-γ) in the gut. Furthermore, studies in LANCL2-/- mice demonstrated that loss of LANCL2 abrogated beneficial actions of 7, suggesting high selectivity for the target. In conclusion, 7 merits continued development as a LANCL2-based, first-in-class orally active therapeutic for IBD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related AChE Products

CAS 312-48-1 Edrophonium

(CAS: 312-48-1)

Edrophonium is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine competitively ...

CAS 122892-31-3 Itopride hydrochloride

Itopride hydrochloride
(CAS: 122892-31-3)

Reversible AChE inhibitor. D2 receptor antagonist. Raises motilin and somatostatin levels. Lowers CCK levels. Shows gastroprokinetic effects in vivo. Orally act...

Neostigmine Iodide
(CAS: 1212-37-9)

This active molecular is a reversible acetylcholinesterase inhibitor as a parasympathomimetic compound under the development of Flamel Technologies. Neostigmine...

CAS 314-03-4 Pimethixene

(CAS: 314-03-4)

Pimethixene, also called as BP 400 or Calmixène, with antihistamine and anticholinergic properties it treats hyperactivity, anxiety, sleep disorders, and allerg...

CAS 51-60-5 Neostigmine Methylsulfate

Neostigmine Methylsulfate
(CAS: 51-60-5)

Neostigmine methyl sulfate is a cholinesterase inhibitor used in the treatment of myasthenia gravis, can not cross the blood-brain barrier.

CAS 510-77-0 Galanthaminone

(CAS: 510-77-0)

Galantamine is a competitive and reversible cholinesterase(AChE) inhibitor, which is used for the treatment of mild to moderate Alzheimer's disease and various ...

CAS 209394-46-7 Ladostigil tartrate

Ladostigil tartrate
(CAS: 209394-46-7)

Ladostigil, also called as TV-3,326, is a novel neuroprotective agent developed to treat neurodegenerative disorders sunch as Alzheimer’s disease. Ladostigil is...

CAS 116-38-1 Edrophonium chloride

Edrophonium chloride
(CAS: 116-38-1)

Edrophonium chloride is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine compe...

CAS 185104-11-4 Acotiamide HCl

Acotiamide HCl
(CAS: 185104-11-4)

Acotiamide HCl is the hydrochloride salt of Acotiamide, a drug for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to ...

CAS 101246-66-6 Phenserine

(CAS: 101246-66-6)

Phenserine, an analog of physostigmine, is an acetylcholinesterase (AChE) inhibitor (IC50= 24 nM) potentially for the treatment of Alzheimer Disease (AD).

CAS 115-79-7 Ambenonium dichloride

Ambenonium dichloride
(CAS: 115-79-7)

Ambenonium dichloride is an extremely selective, potent and rapidly reversible inhibitor of acetylcholinesterase (AChE) with IC50 value of 0.000698 μM. It is us...

CAS 13473-38-6 Pipenzolate

(CAS: 13473-38-6)

Pipenzolate, a muscarinic receptor antagonist, commonly existed as bromide salt form and could be used as a spasmolytic and could probably effective in aid ther...

CAS 59-99-4 Neostigmine

(CAS: 59-99-4)

Neostigmine is a parasympathomimetic compound, which acts as a reversible acetylcholinesterase inhibitor. It is used in the treatment of myasthenia gravis, ogil...

CAS 120786-18-7 (±)-Huperzine A

(±)-Huperzine A
(CAS: 120786-18-7)

Huperzine A exhibited protective effects against d-gal-induced hepatotoxicity and inflamm-aging by inhibiting AChE activity and via the activation of the cholin...

CAS 149062-75-9 CI-1002 hydrochloride

CI-1002 hydrochloride
(CAS: 149062-75-9)

The hydrochloride salt form of CI 1002, an azepinoquinazoline derivative, has been found to be an acetylcholinesterase inhibitor that could probably be effectiv...

CAS 51-15-0 Pralidoxime chloride

Pralidoxime chloride
(CAS: 51-15-0)

Pralidoxime is an antidote to organophosphate pesticides, reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organoph...

CAS 129101-54-8 Rivastigmine Tartrate

Rivastigmine Tartrate
(CAS: 129101-54-8)

Rivastigmine Tartrate is a cholinesterase inhibitor with IC50 of 5.5 μM, and used as a parasympathomimetic or cholinergic agent for the treatment of mild to mod...

CAS 121-54-0 Benzethonium Chloride

Benzethonium Chloride
(CAS: 121-54-0)

Benzethonium chloride is a potent inhibitor of nAChRs, it inhibits α4β2 nAChRs and α7 nAChRs with IC50 of 49 nM and 122 nM, respectively.

CAS 123441-03-2 Rivastigmine

(CAS: 123441-03-2)

Rivastigmine, a carbamate derivative, is a reversible cholinesterase inhibitor that is selective for the central nervous system to treat Alzheimer's Disease.

CAS 120011-70-3 Donepezil HCl

Donepezil HCl
(CAS: 120011-70-3)

Donepezil is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively.

Chemical Structure

CAS 1912399-75-7 BT-11

Quick Inquiry

Verification code

Featured Items